The drug industry has accepted the need to outsource R&D--now, with sales productivity down, and the rising cost and risk of owning too much commercial infrastructure, why not outsource more of the sales effort, too? Big and small pharmas resist the idea but will eventually have to accept it--junior partners in licensing deals are insisting on roles in selling their own products, and Big Pharma must investigate cost-saving solutions.
By Roger Longman
These tea leaves don’t require specialists to read
them.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
